- 中文名稱
QX-314 -bromide) (10 mg)
- 英文名字
- QX-314 -bromide), 2-[(2,6-dimethylphenyl)amino]-N,N,N-triethyl-2-oxo-ethanaminium bromide
- 供應商
- Cayman
- 產品貨號
- 10011032-10
- 產品報價
- ￥420/10 mg
- 產品說明書
- 點擊查看
- 購買方式
- 產品新聞
- 背景資料
- QX-314 is a membrane-impermeant lidocaine derivative that selectively blocks sodium channels on nociceptive neurons when delivered intracellularly via the TRPV1 channel, but is reportedly ineffective with extracellular application. When supplied in combination with 1 uM capsaicin, a TRPV1 receptor agonist, 5 mM QX-314 blocks 98% of sodium current in voltage-clamped nociceptive DRG neurons. QX-314 elicits a long-lasting decrease in the response to painful mechanical and thermal stimuli without imparting the motor deficits -e.g., numbness, paralysis) associated with many conventional local anesthetics. At concentrations ranging from 10-70 mM, peripheral application of QX-314 dose-dependently produces robust local anesthesia with slow onset in the guinea pig intradermal wheal assay, the murine tail-flick test, and the murine sciatic nerve blockade model. However, injection of 0.5-30 mM QX-314 in the lumbar intrathecal space produces neurotoxicity and death in mice.
- 產品描述
- A membrane-impermeant lidocaine derivative that when combined with capsaicin selectively blocks sodium channels on nociceptive neurons via the TRPV1 channel; decreases the pain response without imparting numbness or paralysis associated with other local anesthetics
- 產品形式
- 保存建議
- -20
- 其他
- Cayman Chemical
- 注意
-
該頁面的中文產品信息的翻譯，僅供參考。準確的產品信息請以廠家的英文說明書為準。下單前，請瀏覽說明書確認。
-
